The role of prostatic artery embolization in the management of benign prostatic enlargement in patients with chronic liver disease: a prospective single-center clinical trial
Abstract
To evaluate the efficacy and safety of prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH) in patients with chronic liver disease, with subgroup analysis according to Child–Pugh classification. This prospective single-center clinical study enrolled thirty-four male patients (median age, 65 years; IQR 57–71) with symptomatic BPH and chronic liver disease who were refractory to ≥6 months of medical therapy. Baseline clinical, laboratory, and imaging parameters were recorded. Bilateral or unilateral PAE was performed using calibrated microspheres (100–300 µm and/or 300–500 µm). Functional outcomes, including International Prostate Symptom Score (IPSS), prostate volume, maximum urinary flow rate (Qmax), post-void residual urine volume (PVR), and quality-of-life (QOL) scores, were assessed at 1 and 6 months. Outcomes were analyzed overall and stratified by Child–Pugh classification. Technical success was achieved in all patients, with bilateral embolization in 27 patients (79.4%). Median IPSS decreased from 24.0 at baseline to 18.0 at 1 month (22.2% reduction, p < 0.001) and 12.0 at 6 months (51.7% reduction, p < 0.001), and Qmax increased from 7.4 mL/s to 14.2 mL/s at 6 months (91.9% increase, p < 0.001). PVR and QOL scores also improved significantly (p < 0.001). Both Child–Pugh A (n = 22) and Child–Pugh B (n = 12) improved significantly. Prostate volume decreased more in Child–Pugh B at 1 and 6 months (between-group p < 0.001), while IPSS reduction was…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.